Dec. 1 Quick Takes: New round pushes Abogen’s venture haul over $1B
Plus Hotspot, Apollo, Curie, ICER, Zogenix, Chinook, BeyondSpring
Suzhou Abogen Biosciences Co. Ltd.’s $300 million series C+ round, led by Softbank Vision Fund and series C investor 5Y Capital, brings the Chinese mRNA company’s venture money raised this year to more than $1 billion. New investors joining this round include Chimera Abu Dhabi, Fortune Ocean, Jinyi Capital, New Frontier Group, IMO Ventures, Mirae Asset Financial and DNE capital. In August, Abogen, which has a COVID-19 vaccine in Phase III testing, raised a record-setting $720 million in its series C. The two-year-old company is led by founder and CEO Bo Ying.
Apollo Health Ventures will have $180 million to invest in start-ups focused on aging-related disorders. The Boston and Berlin-based fund announced the final close of its Apollo Health Ventures Fund II, some of which will go toward company creation. Its portfolio includes Aeovian Pharmaceuticals Inc., which is developing a formulation of rapamycin, and autophagy company Samsara Therapeutics Inc...